(9CI)-螺[1-氮杂双环[2.2.2]辛烷-3,5-噁唑啉]-2-酮 | 178419-45-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 中文名称: (9CI)-螺[1-氮杂双环[2.2.2]辛烷-3,5-噁唑啉]-2-酮
• 英文名称: (rac)-spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one
• 英文别名: AAR 17779；ARR 17779；spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one；spiro[1,3-oxazolidine-5,3'-1-azabicyclo[2.2.2]octane]-2-one
• CAS: 178419-45-9
• 化学式: C₉H₁₄N₂O₂
• mdl: MFCD21266569
• 分子量: 182.222
• InChiKey: TYAGAVRSOFABFO-UHFFFAOYSA-N

物化性质

• 沸点：
  411.7±34.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  溴苯 、 (9CI)-螺[1-氮杂双环[2.2.2]辛烷-3,5-噁唑啉]-2-酮 在 copper(l) iodide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以36%的产率得到3-Phenylspiro[1,3-oxazolidine-5,3'-1-azabicyclo[2.2.2]octane]-2-one
  参考文献：
  名称：

  Discovery of the α7 Nicotinic Acetylcholine Receptor Agonists. (R)-3‘-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5‘-[1‘,3‘]oxazolidin-2‘-one as a Novel, Potent, Selective, and Orally Bioavailable Ligand

  摘要：

  Recent advances in molecular biology suggest that neuronal nicotinic acetylcholine receptors play important roles in the central nervous system (CNS). Of these receptors, the 0 group has recently attracted interest for its CNS-related actions and is looked to as a potential new class of pharmacological targets for cognition, schizophrenia, sensory gating, and anxiety. In the course of a research program aimed at the discovery of alpha 7 receptor agonists with high affinity, subtype selectivity, and good pharmacokinetic profile, we discovered (R)-3'(5-chlorothiophen-2-yl)spiro-l-azabicyclo[2.2.2]octane-3,5'-[1',3'loxazolidin-2'-one (25). Compound 25 has potent binding affinity (K-i = 9 nmol/L) and good selectivity toward the other nicotinic subtypes (alpha A beta 2 and a1 beta 2 gamma delta) and has been found in pharmacokinetic evaluation to have good oral bioavailability and brain permeability.

  DOI：

  10.1021/jm049188d
• 作为产物：
  描述：

  (3-Hydroxy-1-aza-bicyclo[2.2.2]oct-3-yl)-acetyl azide 在 盐酸 作用下， 反应 0.33h， 生成 (9CI)-螺[1-氮杂双环[2.2.2]辛烷-3,5-噁唑啉]-2-酮
  参考文献：
  名称：

  (−)-Spiro[1-azabicyclo[2.2.2]octane-3,5‘-oxazolidin-2‘-one], a Conformationally Restricted Analogue of Acetylcholine, Is a Highly Selective Full Agonist at the α7 Nicotinic Acetylcholine Receptor

  摘要：

  Neuronal nicotinic acetylcholine receptors are members of the ligand-gated ion channel receptor superfamily and may play important roles in modulating neurotransmission, cognition, sensory gating, and anxiety. Because of its distribution and abundance in the CNS, the alpha7 nicotinic receptor is a strong candidate to be involved in some of these functions. In this paper we describe the synthesis and in vitro profile of AR-R17779, (-)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one] (4a), a potent full agonist at the rat alpha7 nicotinic receptor, which is highly selective for the rat alpha7 nicotinic receptor over the alpha4 beta2 subtype. Preliminary SAR of AR-R17779 presented here indicate that there is little scope for modification of this rigid molecule as even minor changes result in significant loss of the alpha7 nicotinic receptor affinity.

  DOI：

  10.1021/jm000249r

文献信息

• MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS
  申请人：Macdonald Gregor James

  公开号：US20120238561A1

  公开（公告）日：2012-09-20

  The present invention relates to morpholinothiazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulators having the capability to increase the efficacy of nicotinic receptor agonists.

  本发明涉及吗啉噻唑衍生物及其可药用盐，它们的制备方法，含有它们的药物组合物及其在治疗中的用途。特别是涉及烟酸乙酰胆碱受体的正变构调节剂，这些正变构调节剂具有增加烟酸受体激动剂效力的能力。
• [EN] MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MORPHOLINOTHIAZOLES EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS D'ALPHA 7
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011064288A1

  公开（公告）日：2011-06-03

  The present invention relates to morpholinothiazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulators having the capability to increase the efficacy of nicotinic receptor agonists.

  本发明涉及吗啉噻唑衍生物及其可药用盐，它们的制备方法，含有它们的药物组合物及其在治疗中的用途。本发明特别涉及烟酸乙酰胆碱受体的正变构调节剂，这些正变构调节剂具有增加烟酸受体激动剂效力的能力。
• [EN] TRISUBSTITUTED PYRAZOLES AS ACETYLCHOLINE RECEPTOR MODULATORS<br/>[FR] PYRAZOLES TRISUBSTITUÉS EN TANT QUE MODULATEURS DES RÉCEPTEURS DE L'ACÉTYLCHOLINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009135944A1

  公开（公告）日：2009-11-12

  The present invention relates to 1-alkyl-3-aniline-5-aryl-pyrazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.

  本发明涉及1-烷基-3-苯胺基-5-芳基-吡唑衍生物及其药用盐，制备它们的方法，含有它们的药物组合物以及它们在治疗中的应用，根据式（I）。该发明特别涉及正向变构调节剂对尼古丁乙酰胆碱受体的作用，这种正向变构调节剂具有增加尼古丁受体激动剂效力的能力。
• [EN] 1,3,5-TRISUBSTITUTED TRIAZOLE DERIVATIVE<br/>[FR] DÉRIVÉ DE TRIAZOLE 1,3,5-TRISUBSTITUÉ
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009050185A1

  公开（公告）日：2009-04-23

  The present invention relates to 2-[3-(2,2-Difluoro-benzo[l1,3]dioxol-5-ylamino)-5-(2,6-dimethyl-pyridin-4-yl)-[1,2,4]triazol-1-yl]-N-ethyl-acetamide and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to a potent positive allosteric modulator of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.

  本发明涉及2-[3-(2,2-二氟苯[b]二氧杂环戊烷-5-基氨基)-5-(2,6-二甲基吡啶-4-基)-[1,2,4]三唑-1-基]-N-乙酰基丙酰胺及其类似物或药用盐，制备它们的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及一种对尼古丁型乙酰胆碱受体具有强效的正变构调节剂，具有增加尼古丁受体激动剂效力的能力。
• 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES
  申请人：Thuring Johannes Wilhelmus John F.

  公开号：US20110269748A1

  公开（公告）日：2011-11-03

  This invention concerns the use of a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is hydrogen, halo, C 1-6 alkyl, Het 1 , HO—C 1-6 alkyl-, cyano-C 1-6 alkyl-, amino-C(═O)—C 1-6 alkyl-, formylamino-C 1-6 alkyl-, C 1-6 alkyl-C(═O)—NH—C 1-6 alkyl-, mono- or di(C 1-6 alkyl)amino-C(═O)—C 1-6 alkyl-, phenyl-C 1-6 alkyl-, or Het 4 -C 1-6 alkyl-; Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C 1-6 alkyl, C 1-6 alkyl-O—, C 1-6 alkylthio, Ar or polyhaloC 1-6 alkyl; L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C 1-6 alkyl or C 1-6 alkyl-O—; Het 1 represents morpholinyl; pyrazolyl or imidazolyl; Het 4 represents morpholinyl, pyrazolyl or imidazolyl; Ar represents phenyl optionally substituted with halo, C 1-6 alkyl, C 1-6 alkyl-O— or polyhaloC 1-6 alkyl; for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the α7 nicotinic receptor is beneficial.

  这项发明涉及使用式(I)中的化合物，其中N-氧化物是药用可接受的加合盐，季铵基和其立体化异构形式，其中Z为氢、卤素、C1-6烷基、Het1、HO—C1-6烷基、氰基-C1-6烷基、氨基-C(═O)—C1-6烷基、甲酰氨基-C1-6烷基、C1-6烷基-C(═O)—NH—C1-6烷基、单烷基或二烷基胺基-C(═O)—C1-6烷基、苯基-C1-6烷基或Het4-C1-6烷基；Q为苯基、吡啶基、苯并呋喃基、2,3-二氢苯并呋喃基、吡唑基、异噁唑基或吲唑基，其中每个环系统可选地被取代，每个取代基可独立地选择自卤素、氰基、C1-6烷基、C1-6烷基-O—、C1-6烷基硫醚、Ar或多卤代C1-6烷基；L为苯基、吡啶基、嘧啶嗪基、8-吡啉嗪基、吡啶嗪基、咪唑噻唑基或呋喃基，其中每个环系统可选地被取代，每个取代基可独立地选择自卤素、羟基、氨基、氰基、C1-6烷基或C1-6烷基-O—；Het1代表吗啉基；吡唑基或咪唑基；Het4代表吗啉基、吡唑基或咪唑基；Ar代表苯基，可选地被卤素、C1-6烷基、C1-6烷基-O—或多卤代C1-6烷基取代；用于制备一种用于预防或治疗或预防精神障碍、智力障碍或调节α7尼古丁受体有益的疾病或情况的药物。